Medtech Trends 2026: Reshaping North America's Manufacturing and Trade Landscape

How global medtech dynamics are steering investment and cross-border commerce within the USMCA region

Executive Summary

The medical technology industry is entering a period of accelerated structural change. Pricing pressures in China, the continued migration of procedures to outpatient settings, trade and supply chain volatility, the rise of GLP-1 therapies, and the expansion of platform-based competition are all forcing companies to re-evaluate their manufacturing footprints and market strategies. For North America, these trends are not only affecting corporate profitability; they are reshaping regional trade flows, investment decisions, and industrial policy under the United States-Mexico-Canada Agreement (USMCA). This article analyzes the trade and manufacturing implications for the United States, Canada, and Mexico over the next three to five years.

Introduction

For years, the medtech industry has operated on a familiar set of assumptions: production in low-cost regions, regulated market access through major health authorities, and procedure growth driven by hospital-based care. Those assumptions are now breaking down. A convergence of policy changes, technological shifts, and geopolitical disruptions is prompting companies to rethink where they make devices, how they price them, and how they compete. North America, as a highly integrated regional market with a strong manufacturing base and advanced technology ecosystem, is both a beneficiary of these shifts and a source of strategic responses.

Main Analysis

China’s Volume-Based Procurement (VBP) Expansion

China’s national VBP program has evolved from a cost-containment mechanism into a market-structuring force. The latest rounds introduce anchor-pricing formulas that create steep price reductions while allocating volume disproportionately to domestic suppliers. For multinational medtech corporations, this means margins on devices sold in China will compress further. In response, companies are likely to accelerate moves to lower-cost production bases for global export. Mexico, with its established medical device clusters and proximity to the U.S. market, is emerging as a natural candidate for rebalancing manufacturing capacity. This does not necessarily mean exiting China—still a major growth market—but it does mean that North America could capture a larger share of production for export to the Americas and beyond.

Outpatient and ASC Migration

The U.S. Centers for Medicare & Medicaid Services (CMS) 2026 Hospital Outpatient Prospective Payment System (OPPS) and Ambulatory Surgical Center (ASC) Payment System Final Rule continues to expand the list of procedures eligible for ASC reimbursement. Higher-acuity procedures like cardiac ablation are increasingly moving out of hospital settings. This shift carries direct consequences for medtech companies: device portfolios must be re-designed for the logistical realities of outpatient clinics, which favor smaller instruments, simpler workflows, and efficient packaging. For supply chains, the move from centralized hospital procurement to distributed outpatient clinics means more frequent, smaller shipments. This requires a more responsive logistics network, potentially benefiting regional distribution centers in the U.S. and cross-border freight operations aligned with just-in-time delivery.

Trade and Supply Chain Pressures

Tariff exposure and geopolitical uncertainty have made supply chain resilience a board-level priority. Earlier assumptions that offshoring to Asia would yield the lowest cost are being reconsidered as companies factor in tariffs, shipping risks, and the need for flexibility. The medical device sector is highly dependent on electronic components, plastics, and specialty metals; disruptions in these inputs can halt production lines. To mitigate these risks, companies are diversifying suppliers and building multi-region manufacturing networks. North America is an attractive destination for such diversification, particularly Mexico, where the medical device industry already exports over $20 billion annually to the United States. USMCA rules of origin for medical devices, combined with regulatory alignment through the Medical Device Single Audit Program, make it easier to integrate supply chains across the three countries.

GLP-1 Therapies and Clinical Pathway Disruption

The rapid adoption of glucagon-like peptide-1 (GLP-1) receptor agonists for obesity and diabetes is beginning to reshape medical device markets. While bariatric surgery remains an effective intervention for severe obesity, its growth has slowed in some segments as patients turn to pharmacological weight-loss options. This is affecting manufacturers of bariatric devices, but the ripple effects are broader: the management of metabolic disease increasingly involves continuous glucose monitoring, cardiac monitors, and sleep apnea devices. In North America, where metabolic disease prevalence is high, this is likely to spur new product development and cross-border research collaborations. The integration of pharmaceutical and device approaches also creates opportunities for medtech firms to partner with drug companies, though pricing pressure on both sides remains a concern.

Platform-Based Competition and Enabling Technologies

Robotics, imaging, navigation, and digital workflow software are converging into integrated platforms that define the standard of care. Companies that can offer a complete ecosystem—from pre-operative planning to intraoperative execution and post-operative follow-up—gain a significant competitive advantage. This trend is accelerating investment in software, data analytics, and artificial intelligence across the industry. For North America, this is a strong suit: the region hosts many of the world’s leading digital health and AI firms, and there is a deep pool of engineering talent across the three countries. The challenge for policymakers is to ensure that data-sharing regulations and intellectual property protections encourage innovation without creating barriers to cross-border integration.

Trade Impact

The medtech trends outlined above are directly influencing trade patterns in North America. First, the long-term shift of manufacturing to Asia is reversing. The USMCA is encouraging regional value content, and new investment incentives from the U.S. government, including the CHIPS Act and the Inflation Reduction Act, are supporting advanced manufacturing more broadly. While these bills are not medtech-specific, they improve the broader industrial ecosystem. Second, customs modernization and trade facilitation under USMCA are helping to streamline cross-border shipments of medical devices and components, reducing lead times for companies operating integrated supply chains.

Third, the emphasis on supply chain resilience is likely to lead to a bifurcated production strategy: keep high-value, technology-intensive manufacturing in the U.S. and Canada, while moving mid-volume, cost-sensitive production to Mexico. This division of labor aligns with each country’s comparative advantage.

Regional Perspective

• United States: The United States is the world’s largest medtech market and will continue to drive demand. Policy emphasis on domestic manufacturing and technology leadership is creating a favorable environment for investment. However, tariff policy uncertainty is a double-edged sword: it may shield domestic producers, but it also raises costs for components not yet produced locally. Companies are expected to use U.S.-based facilities for high-end assembly and final testing, while leveraging Mexico for labor-intensive sub-assemblies.
• Canada: Canada’s medtech sector is known for innovation in medical imaging, diagnostics, and digital health. The country’s membership in USMCA gives it preferential access to U.S. and Mexican markets. Canadian firms are likely to benefit from increased R&D collaboration and from the regional demand for platform technologies. The country’s stable political environment and investment in artificial intelligence make it a key partner in the transition to digital manufacturing.
• Mexico: Mexico is the most immediate beneficiary of nearshoring. Its medical device manufacturing industry, centered in Baja California, Chihuahua, and Tamaulipas, is well-positioned to absorb new investments. However, Mexico must address infrastructure gaps—especially in electricity and water—to support more advanced manufacturing. Labor availability and training are also concerns; the industry needs more engineers and technicians to move up the value chain. If Mexico can modernize its industrial parks and logistics corridors, it is poised to become the manufacturing backbone of the North American medtech industry.

Future Outlook

Looking ahead to 2030, several developments are likely to shape the medtech landscape in North America:

• More integrated regional supply chains: The trend toward nearshoring will deepen as companies seek to reduce lead times and mitigate trade risk. Cross-border logistics infrastructure—ports, rail, highways, and border crossings—will require sustained investment to handle increased freight volumes.
• Artificial intelligence in manufacturing: AI will play an expanding role in quality control, predictive maintenance, and supply chain optimization. North American manufacturers that adopt AI-linked systems will gain a significant advantage in cost and speed.
• Energy and sustainability: The energy transition will affect medtech manufacturing, particularly the availability of reliable electricity for factories. Mexico’s investment in renewable energy could become a selling point for its manufacturing sector.
• Critical materials: The production of semiconductors and rare-earth elements used in medical devices will become more strategic. North America’s push to secure critical mineral supply chains will intersect with medtech’s need for advanced components.
• Policy convergence: Regulatory harmonization across the USMCA region will likely accelerate, reducing time to market for new devices and enabling more cross-border trials and data sharing.

Key Takeaways

• The five medtech trends—China’s VBP expansion, outpatient migration, supply chain pressure, GLP-1 disruption, and platform technologies—are driving a strategic reconfiguration of North America’s medical device industry.
• Nearshoring to Mexico is accelerating, with USMCA rules and regulatory alignment supporting regional integration.
• Tariff exposure and supply chain volatility are pushing manufacturers to diversify beyond Asia, benefiting the United States, Canada, and Mexico.
• The shift to outpatient care is changing product design and logistics, favoring agile distribution networks.
• GLP-1 therapies are reducing demand for certain bariatric devices while opening opportunities in related monitoring and diagnostic categories.
• Platform-based competition is elevating the importance of software, AI, and data analytics, areas where North America has a strong competitive edge.

Sources

• Clarivate, "5 medtech trends to watch in 2026" — Link